Measuring the impact of the updated Steatotic liver disease nomenclature and definition

Luca Valenti^{1

2}, Alessio Aghemo^{3

4}, Alejandro Forner^{5

6}, Salvatore Petta⁷, Stefano Romeo^{8

9

10}, Pierre Nahon^{11

12

13}

Affiliations

¹ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
² Precision Medicine, Biological Resource Center and Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
³ Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.
⁴ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁵ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, ICMDM, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
⁶ Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
⁷ Sezione di Gastroenterologia e Epatologia, Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro", University of Palermo, Palermo, Italy.
⁸ Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁹ Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden.
¹⁰ Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy.
¹¹ APHP, Liver Unit, Bobigny, France.
¹² Université Sorbonne Paris Nord, F-93000, Bobigny, France.
¹³ Inserm, UMR-1138 "Functional Genomics of Solid Tumors", Centre de Recherche des Cordeliers, Université de Paris, Paris, France.

Editorial

Luca Valenti et al. Liver Int. 2023 Nov.

. 2023 Nov;43(11):2340-2342.

doi: 10.1111/liv.15731.

Luca Valenti^{1

2}, Alessio Aghemo^{3

4}, Alejandro Forner^{5

6}, Salvatore Petta⁷, Stefano Romeo^{8

9

10}, Pierre Nahon^{11

12

13}

¹ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
² Precision Medicine, Biological Resource Center and Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
³ Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.
⁴ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁵ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, ICMDM, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
⁶ Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
⁷ Sezione di Gastroenterologia e Epatologia, Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro", University of Palermo, Palermo, Italy.
⁸ Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁹ Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden.
¹⁰ Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy.
¹¹ APHP, Liver Unit, Bobigny, France.
¹² Université Sorbonne Paris Nord, F-93000, Bobigny, France.
¹³ Inserm, UMR-1138 "Functional Genomics of Solid Tumors", Centre de Recherche des Cordeliers, Université de Paris, Paris, France.

No abstract available

Comment on

Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Ciardullo S, et al. Liver Int. 2023 Nov;43(11):2425-2433. doi: 10.1111/liv.15695. Epub 2023 Aug 17. Liver Int. 2023. PMID: 37592856

1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-209.
1. Mendez-Sanchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388-390.
1. Farahat TM, Ungan M, Vilaseca J, et al. The paradigm shift from NAFLD to MAFLD: a global primary care viewpoint. Liver Int. 2022;42(6):1259-1267.
1. Mantovani A, Valenti L. A call to action for fatty liver disease. Liver Int. 2021;41(6):1182-1185.
1. Bianco C, Romeo S, Petta S, Long MT, Valenti L. MAFLD vs. NAFLD: let the contest begin! Liver Int. 2020;40(9):2079-2081.